Affluent Medical SA · ISIN: FR0013333077 · EQS - Company News

H1 2024 RESULTS - Major advances in all three programs - Several strategic agreements signed with the world medtech leader in cardiology - Extension of financial runway

PRESS RELEASE  H1 2024 RESULTS Major advances in all three programs Several strategic agreements signed with the world medtech leader in cardiology Extension of financial runway to July 2025  Several agreements signed in July 2024 with Edwards Lifesciences for an initial amount of €15m and an option to acquire the rights for KaliosTM Positive feedback from the Food & Drug Administration (FDA) to accelerate access to the US market for KaliosTM through a simple De Novo or 510K pathway ...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Affluent Medical SA

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
26 September 2024 05:45PM
H1 2024 RESULTS - Major advances in all three programs - Several strategic agreements signed with the world medtech leader in cardiology - Extension of financial runway
PRESS RELEASE  H1 2024 RESULTS Major advances in all three programs Several strategic agreements signed with the world medtech leader in cardiology Extension of financial runway to July 2025  Several agreements signed in July 2024 with Edwards Lifesciences for an initial amount of €15m and an option to acquire the rights for KaliosTM Positiv...
Affluent Medical SA
12 July 2024 07:45AM
Affluent Medical signs agreements for mitral valve technologies with EUR 15M upfront payment
Affluent Medical signs agreements for mitral valve technologies with EUR 15M upfront payment   Aix-en-Provence, July 12, 2024 - 7:45 am - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME - “Affluent”), a French clinical-stage medical technology company specializing in the international development and industrialization of innovative medical dev...
Affluent Medical SA
28 September 2023 05:45PM
H1 2023 RESULTS - Major advances in clinical programs - Extension of cash horizon to February 2024
H1 2023 RESULTS Major advances in clinical programs Extension of cash horizon to February 2024   Progress in structural heart activities: First successful implantation of the Epygon valve and continuation of the pilot study Excellent clinical results for Kalios in terms of efficacy and an excellent 1-year safety profile Financing of clin...
Affluent Medical SA
13 September 2023 05:45PM
Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities
PRESS RELEASE  Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities KaliosTM adjustable ring for mitral valve repair with positive 1-year results: - Pivotal Optimise II study with 20 patients demonstrated efficacy at 1 year and excellent safety profile - Results drove s...
Affluent Medical SA
17 July 2023 07:30AM
Affluent Medical strengthens management team to advance its development
Affluent Medical strengthens management team to advance its development   Aix-en-Provence, July 17, 2023 – 07:30 am CET - Affluent Medical (Euronext Paris: FR0013333077 – AFME), a French clinical-stage MedTech company specialized in the international development and commercialization of innovative medical prostheses to treat mitral heart valve pat...
Affluent Medical SA
17 July 2023 07:30AM
Affluent Medical strengthens management team to advance its development
Affluent Medical strengthens management team to advance its development   Aix-en-Provence, July 17, 2023 – 07:30 am CET - Affluent Medical (Euronext Paris: FR0013333077 – AFME), a French clinical-stage MedTech company specialized in the international development and commercialization of innovative medical prostheses to treat mitral heart valve pat...
Affluent Medical SA
28 June 2023 01:00PM
Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt
Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt  Transcatheter mitral valve implantation with Epygon prosthesis in E-poster session at CSI Device is the only biomimetic transcatheter cardiac mitral valve in development that mimics the native mitral valve and restores physiological...
Affluent Medical SA
28 June 2023 01:00PM
Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt
Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt  Transcatheter mitral valve implantation with Epygon prosthesis in E-poster session at CSI Device is the only biomimetic transcatheter cardiac mitral valve in development that mimics the native mitral valve and restores physiological...
Affluent Medical SA
More Affluent Medical SA related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN